EP2846794 - BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE [Right-click to bookmark this link] | |||
Former [2015/12] | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE | ||
[2017/25] | Status | No opposition filed within time limit Status updated on 07.09.2018 Database last updated on 14.06.2024 | |
Former | The patent has been granted Status updated on 29.09.2017 | ||
Former | Grant of patent is intended Status updated on 21.05.2017 | Most recent event Tooltip | 17.07.2020 | Lapse of the patent in a contracting state New state(s): AL | published on 19.08.2020 [2020/34] | Applicant(s) | For all designated states Merck Sharp & Dohme Corp. 126 East Lincoln Avenue Rahway, NJ 07065 / US | For all designated states Lycera Corporation 2800 Plymouth Rd. NCRC Building 26 Ann Arbor, MI 48109 / US | [2015/12] | Inventor(s) | 01 /
AICHER, Thomas 162 Rockwood Court Ann Arbor, Michigan 48103 / US | 02 /
BARR, Kenneth 33 Avenue Louis Pasteur Boston, Massachusetts 02115 / US | 03 /
SIMOV, Vladimir 33 Avenue Louis Pasteur Boston, Massachusetts 02115 / US | 04 /
THOMAS, William 1803 Charmeran Avenue San Jose, California 95124 / US | 05 /
TOOGOOD, Peter 2281 Sun Valley Drive Ann Arbor, Michigan 48108 / US | 06 /
VAN HUIS, Chad 13850 Plover Drive Hartland, Michigan 48353 / US | [2015/12] | Representative(s) | Harris, Jennifer Lucy, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2017/44] |
Former [2015/12] | Harris, Jennifer Lucy, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB | Application number, filing date | 13787211.5 | 03.05.2013 | [2017/44] | WO2013US39422 | Priority number, date | US201261644143P | 08.05.2012 Original published format: US 201261644143 P | [2015/12] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2013169588 | Date: | 14.11.2013 | Language: | EN | [2013/46] | Type: | A1 Application with search report | No.: | EP2846794 | Date: | 18.03.2015 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.11.2013 takes the place of the publication of the European patent application. | [2015/12] | Type: | B1 Patent specification | No.: | EP2846794 | Date: | 01.11.2017 | Language: | EN | [2017/44] | Search report(s) | International search report - published on: | US | 14.11.2013 | (Supplementary) European search report - dispatched on: | EP | 18.11.2015 | Classification | IPC: | A61K31/352, C07D213/82, C07D215/38, C07D217/22, C07D223/16, C07D231/18, C07D233/72, C07C311/40, C07D401/12, A61P37/00, A61P29/00 | [2015/51] | CPC: |
A61P1/04 (EP);
C07C317/14 (KR);
C07D213/82 (EP,CN,US);
C07C317/40 (US);
A61K31/18 (KR);
A61P1/16 (EP);
A61P11/00 (EP);
A61P11/06 (EP);
A61P17/00 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P21/00 (EP);
A61P21/04 (EP);
A61P25/00 (EP);
A61P29/00 (EP);
A61P3/10 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
A61P37/08 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP);
C07C311/30 (EP,CN,US);
C07C317/12 (KR);
C07D207/12 (EP,CN,US);
C07D207/27 (EP,CN,US);
C07D209/52 (EP,CN,US);
C07D211/96 (EP,CN,US);
C07D215/38 (EP,CN,US);
C07D217/22 (EP,CN,US);
C07D223/16 (EP,CN,US);
C07D231/18 (EP,CN,US);
C07D233/72 (EP,CN,US);
C07D263/22 (EP,CN,US);
C07D263/44 (EP,CN,US);
C07D401/12 (EP,CN,US);
C07D471/04 (EP,CN,US);
C07D491/052 (EP,CN,US);
C07C2601/02 (EP,CN,US);
C07C2601/14 (EP,CN,US);
C07C2602/00 (EP,US);
C07C2602/10 (EP,CN,US);
|
Former IPC [2015/12] | A61K31/352 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/12] | Extension states | BA | 07.11.2014 | ME | 07.11.2014 | Title | German: | BICYCLISCHE SULFONVERBINDUNGEN ZUR HEMMUNG DER RORgamma-AKTIVITÄT UND ZUR BEHANDLUNG VON ERKRANKUNGEN | [2017/25] | English: | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | [2017/25] | French: | COMPOSÉS SULFONE BICYCLIQUES UTILISÉS POUR L'INHIBITION DE L'ACTIVITÉ RORgamma ET LE TRAITEMENT D'UNE MALADIE | [2017/25] |
Former [2015/12] | BICYCLISCHE SULFONVERBINDUNGEN ZUR HEMMUNG DER RORY-AKTIVITÄT UND ZUR BEHANDLUNG VON ERKRANKUNGEN | ||
Former [2015/12] | BICYCLIC SULFONE COMPOUNDS FOR INHIBITION OF RORy ACTIVITY AND THE TREATMENT OF DISEASE | ||
Former [2015/12] | COMPOSÉS SULFONE BICYCLIQUES UTILISÉS POUR L'INHIBITION DE L'ACTIVITÉ ROR ET LE TRAITEMENT D'UNE MALADIE | Entry into regional phase | 07.11.2014 | National basic fee paid | 07.11.2014 | Search fee paid | 07.11.2014 | Designation fee(s) paid | 07.11.2014 | Examination fee paid | Examination procedure | 07.11.2014 | Examination requested [2015/12] | 13.06.2016 | Amendment by applicant (claims and/or description) | 22.05.2017 | Communication of intention to grant the patent | 22.09.2017 | Fee for grant paid | 22.09.2017 | Fee for publishing/printing paid | 22.09.2017 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.05.2017 | Opposition(s) | 02.08.2018 | No opposition filed within time limit [2018/41] | Fees paid | Renewal fee | 12.05.2015 | Renewal fee patent year 03 | 27.05.2016 | Renewal fee patent year 04 | 30.05.2017 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 03.05.2013 | AL | 01.11.2017 | AT | 01.11.2017 | CY | 01.11.2017 | CZ | 01.11.2017 | DK | 01.11.2017 | EE | 01.11.2017 | ES | 01.11.2017 | FI | 01.11.2017 | HR | 01.11.2017 | IT | 01.11.2017 | LT | 01.11.2017 | LV | 01.11.2017 | MC | 01.11.2017 | MK | 01.11.2017 | NL | 01.11.2017 | PL | 01.11.2017 | PT | 01.11.2017 | RO | 01.11.2017 | RS | 01.11.2017 | SE | 01.11.2017 | SI | 01.11.2017 | SK | 01.11.2017 | SM | 01.11.2017 | TR | 01.11.2017 | BG | 01.02.2018 | NO | 01.02.2018 | GR | 02.02.2018 | IS | 01.03.2018 | IE | 03.05.2018 | LU | 03.05.2018 | MT | 03.05.2018 | BE | 31.05.2018 | CH | 31.05.2018 | LI | 31.05.2018 | [2020/34] |
Former [2020/31] | HU | 03.05.2013 | |
AT | 01.11.2017 | ||
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
MK | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
PT | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
TR | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
MT | 03.05.2018 | ||
BE | 31.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2020/28] | HU | 03.05.2013 | |
AT | 01.11.2017 | ||
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
PT | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
TR | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
MT | 03.05.2018 | ||
BE | 31.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2020/16] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
TR | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
MT | 03.05.2018 | ||
BE | 31.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2020/08] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
MT | 03.05.2018 | ||
BE | 31.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2019/24] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
BE | 31.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2019/19] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
IE | 03.05.2018 | ||
LU | 03.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2019/17] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
LU | 03.05.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2019/12] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
CH | 31.05.2018 | ||
LI | 31.05.2018 | ||
Former [2019/06] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
MC | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/52] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SI | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/40] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RO | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/39] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
IT | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/37] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
PL | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SK | 01.11.2017 | ||
SM | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/35] | AT | 01.11.2017 | |
CY | 01.11.2017 | ||
CZ | 01.11.2017 | ||
DK | 01.11.2017 | ||
EE | 01.11.2017 | ||
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
SK | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/24] | AT | 01.11.2017 | |
ES | 01.11.2017 | ||
FI | 01.11.2017 | ||
HR | 01.11.2017 | ||
LT | 01.11.2017 | ||
LV | 01.11.2017 | ||
NL | 01.11.2017 | ||
RS | 01.11.2017 | ||
SE | 01.11.2017 | ||
BG | 01.02.2018 | ||
NO | 01.02.2018 | ||
GR | 02.02.2018 | ||
IS | 01.03.2018 | ||
Former [2018/22] | ES | 01.11.2017 | |
FI | 01.11.2017 | ||
LT | 01.11.2017 | ||
NL | 01.11.2017 | ||
NO | 01.02.2018 | Documents cited: | Search | [A]WO2010049144 (PHENEX PHARMACEUTICALS AG [DE], et al) [A] 1-15 * abstract * * figure 2 *; | CN101580874 [ ] (UNIV JIANGSU [CN]) | [A] - WANG, SHENGJUN ET AL, "Fluorescence quantitative PCR method for detecting human ROR.gamma.t transcripts in peripheral blood", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2009:1446746, URL: STN, XP002750171 [A] 1-15 * abstract * | International search | [A]JPH06250441 (NIPPON KAYAKU KK); | [A]US2007049556 (ZHANG XUQING [US], et al); | [A]WO2010017827 (EUROPEAN MOLECULAR BIOLOGY LAB EMBL [DE], et al); | [A]US2008153805 (CECCARELLI SIMONA M [CH], et al) | by applicant | WO2010049144 | - Handbook of experimental immunology |